MedTrace Logo

Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis

NCT04886258 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2026-03-31

Study results available
· View outcomes & findings →

Summary

This was a double-blinded, two-arm, phase 2a study to assess efficacy, safety and tolerability of DFV890 in participants with symptomatic knee osteoarthritis.

Conditions

  • Symptomatic Knee Osteoarthritis

Interventions

DRUG

DFV890

DFV890 was administered orally twice per day, 10 mg during 2 weeks and 25 mg during the next 10 weeks.

DRUG

Placebo

Matching Placebo was administered orally twice per day during 12 weeks.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-20
Primary Completion
2024-12-14
Completion
2024-12-23
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Czechia
  • Germany
  • Hungary
  • Romania
  • Slovakia
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04886258 on ClinicalTrials.gov